NERV / Minerva Neurosciences (NERV) Reports Q4 Loss, Misses Revenue Estimates

Minerva Neurosciences has raised $20M through a private placement at a premium to market prices. Boehringer Ingelheim participated in the private plac more_horizontal

Minerva Neurosciences (NERV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In additio more_horizontal

NERV has once again run on the submission of an NDA for roluperidone for the treatment of negative symptoms in schizophrenia. There will be no Refusal more_horizontal

BURLINGTON, Mass., May 08, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on more_horizontal

Minerva Neurosciences, Inc. (NASDAQ:NERV ) Q4 2022 Earnings Conference Call March 8, 2023 8:30 AM ET Company Participants Geoff Race - President Remy more_horizontal

Minerva (NERV) confirmed that the FDA's refuse-to-file letter on its regulatory filing, seeking approval for roluperidone, to treat symptoms of schizo more_horizontal

Minerva Neurosciences, Inc. (NASDAQ:NERV ) Q3 2022 Earnings Conference Call November 9, 2022 8:30 AM ET Company Participants Geoff Race - President Re more_horizontal

Shares of Minerva Neurosciences (NASDAQ: NERV ) are soaring higher by over 70%  following a purchase by Steve Cohen's Point72 Asset Management and th more_horizontal